Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.
Fiche publication
Date publication
juillet 2020
Journal
International urology and nephrology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Copur S, Sag AA, Afsar B, Rossignol P, Covic A, Kanbay M
Lien Pubmed
Résumé
Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.
Mots clés
Alkaline treatment, Bicarbonate, Chronic kidney disease, End-stage renal disease, Metabolic acidosis
Référence
Int Urol Nephrol. 2020 Jul 13;: